Dong-A ST is challenging the substance patent of AstraZeneca’s SGLT-2 inhibitor antidiabetic treatment ‘Forxiga (dapagliflozin).’

The industry’s eyes are focused on Dong-A ST’s challenge, with the expectation that Dong-A ST’s success would bring a new strategy that can overcome the substance patent of originals.

However, Dong-A ST’s attempt has been put to a stop by the Patent Court of Korea. The final decision will be made by the Supreme Court, but attention is focused on why the Patent Court of Korea overturned the first instance court's ruling and ruled in favor of AstraZeneca in its appeal against Dong-A ST.

◆ "Clear difference between the original drug and

Kim, Jin-Gu(kjg@dailypharm.com)